Daniel Henry, Non-Executive Chairman

Daniel Henry is an experienced senior executive and management consultant with a broad international background and more than 30 years of top level management experience in the healthcare industry.  He was with Merck KgaA for 29 years and for 16 of those years he was CFO and Managing Director of Merck France. In his role as Managing Director he was responsible for business units with €1.13 billion in sales and 4,200 employees. During his time working for Merck in France he completed 11 acquisitions. Latterly Daniel has had considerable success as a consultant or business ‘coach’ to several small and medium size companies in diverse industries where he has advised on finance, corporate strategy and development, mergers and acquisitions, strategic sourcing and management of information systems. He has a Masters Degree in accountancy from Reims University and an Executive MBA from HEC Paris (École des Hautes Études Commerciales de Paris). He is a partner and co-founder of Covivium, a corporate finance consultancy.

Robert has 30 years experience in the natural products industry in the United States, Europe and China and was a major figure in the establishment of Chinese herbal medicine in the UK in the 1980s. He has broad experience in the areas of product development, manufacturing, quality control, and regulatory affairs relating to natural products. In 1997 he founded East West Biotech Limited, a company using proteomic technology for the development and quality control of botanical drugs which was acquired by Oxford Natural Products Limited (ONP) in 1999. Following the acquisition, he was responsible for business development at ONP until October 2000.  Robert co-founded Phynova in 2002.

Keith Thomson, Chief Operating Officer & Chief Financial Officer

Keith has a degree in International Economics and qualified as a Chartered Accountant with KPMG. He has considerable senior management experience from working in several large multinational businesses as well as private equity funded businesses where he has held CEO, COO and CFO positions. Keith has extensive international experience and has an in depth knowledge of working with China. He has guided a number of international healthcare businesses through value enhancing periods in which revenues and market caps were increased: including On Medica an international E-detailing business, Verigen a German based multinational tissue engineering business and Vision RT, a technology business that developed 3d surface imaging technology that is utilised to improve the efficacy of radiotherapy treatment. Keith has a strong track record of creating shareholder value and extensive City & M&A experience. Working in the technology and financial sectors he took Rolfe & Nolan plc a main listed software company private doubling the shareholder value and was International CFO for E*TRADE the international stockbroker. Before joining Phynova, Keith was COO and CFO at Phytopharm plc where he successfully re-structured the business and enabled the company to close a £25 million fundraising event. Keith is a non-executive trustee of project HOPE UK, an International Healthcare Charity.

Michael has been a partner since 1995 in Anvil Partners LLP, a corporate finance advisory firm, where he specialises in raising finance for management buy-outs and development capital and advising on private M&A transactions. He previously spent 18 years in investment banking advising on M&A transactions in London, New York and Paris with Kleinwort Benson and qualified as an accountant with Price Waterhouse in Paris.

Christopher Shaw graduated from MIT with degrees in Mathematics and Metallurgy.  Christopher is a successful entrepreneur of longstanding. In 1964 he founded Micro Metalsmiths, a company specialising in the manufacture of radar components. In 1971 he founded Spectra-Tek UK Ltd, which makes instrumentation for oil and gas metering systems.  He had a joint venture with British Steel to manufacture steel castings, including those for nuclear submarines. He has been an investor and actively involved in a number of start-up companies.  Christopher served for six years as a Governor of Teesside University.  He also served on the Rural Development Commission for North Yorkshire and the North Yorkshire Training and Enterprise Council.  He has had business interests in China since 1981.  He is currently developing new products for sailing boats and musical instruments.

Hongwen Yu, Executive Vice President

Hongwen was a lecturer in the Department of Pharmacy, Shanghai University. She has worked for several companies which were developing medicines from plants. She is experienced in the development of plant-based medicines from "field to final dosage form". She has prepared the initial Chemistry, Manufacturing and Control (CMC) documents for submission to ethics committees and regulatory bodies for clinical trial approval and has successfully managed several development programmes from concept to products in clinical phase. As a Pharmacognosist, she is experienced in the authentication and quality assessment of natural products.

Ian Scoular PhD DMS, Director of Business Development

Ian has more than 20 years marketing and business development expertise in the pharmaceutical industry and experience in Rx, OTC and biotechnology. He has been responsible for identifying, assessing, structuring and negotiating many different types of commercial agreements. He led negotiations with AstraZeneca, resulting in the major licensing agreement with Protherics in December 2005. This deal was recognised at the 2006 Scrip Awards as 'Licensing Deal of the Year'. Ian started his industry career at Reckitt & Colman Pharmaceutical Division in Hull where he and Brian Whittle were colleagues.

Andrew graduated with an MSc from the University of Natal in South Africa in which he investigated the phytochemistry and biological activity of traditional South African medicinal plants. He has previously worked as a lecturer at the University of Natal, where he taught biochemistry and developmental biology, and for an international clinical research organisation in a business development role. In his current role, he oversees the company's research and development programme, where he is responsible for the management and co-ordination of all research and development projects.

Brian has over forty years experience in the pharmaceutical industry and is a specialist in the development of plant-based medicines. He was co-founder of Phytopharm plc and GW Pharma.  Brian is a Fellow of the Royal Pharmaceutical Society, The Linnean Society and of the British Institute of Regulatory Affairs. He was awarded a B Pharm degree from the University of Nottingham in 1954, a PhC Diploma by the Pharmaceutical Society in 1954, an MSc by the University of London in 1957 and a PhD also by the University of London in 1964.

Huaying is a VP for The Coca Cola Company, Greater China, and has previously held the role of Director, Health and Wellness for Asia, The Coca Cola Company, with a primary focus on health and nutrition beverages.  Originally from China, Huaying was previously an officer in the Chinese Ministry of Health, before moving to the USA.  She earned her MD from Beijing University, a Masters in Public Health from Rutgers University  and an MBA from the University of Western Ontario.  She also has a PhD in TCM from the China Academy of Chinese Medical Sciences.

The board has established an audit committee and a remuneration committee both with formally delegated duties and responsibilites. The audit committee and the remuneration committee comprises of Daniel Henry, as the Chairman, and Michael Martin. The nominations committee comprises of Daniel Henry, as the Chairman, and Michael Martin.

The audit committee will receive and review reports from the Company's management and the Company's auditors relating to the annual and interim accounts and the accounting and internal control systems in use throughout the Group. The audit committee will have unrestricted access to the Group's auditors.

The remuneration committee will review the scale and structure of the Executive Directors' remuneration and the terms of their service contracts. The remuneration and terms and conditions of appointment of the Non-Executive Directors will be set by the Board. No Director may participate in any meeting at which discussion or decision regarding his own remuneration takes place. The remuneration committee will also administer any share option schemes and share incentive scheme.